(P121) Image-Guided Radiation Therapy Utilization and Practice Patterns: Results From a National Survey of ASTRO Membership

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

IGRT use is widespread, without standardization of pretreatment imaging modality, frequency, or verification process. Additionally, PTV margin size selection does not appear to be based on IGRT frequency or method of verification. Further research aimed at optimizing IGRT techniques is needed to ensure accurate, safe, timely, and cost-effective treatment delivery.

Nima Nabavizadeh, MD, David A. Elliott, MD, Aaron Kusano, MD, Yiyi Chen, PhD, Timur Mitin, MD, PhD, John M. Holland; Oregon Health and Science University; University of Washington

INTRODUCTION: Image-guided radiation therapy (IGRT) practices differ widely across institutions, with no consensus regarding ideal pretreatment imaging modality, frequency, or verification process. The purpose of this study is to survey clinical IGRT practice patterns and their impact on clinical workflow.

METHODS: A total of 5,979 surveys were emailed to the membership of the American Society of Radiation Oncology (ASTRO). The disease site–specific survey consisted of questions pertaining to planning target volume (PTV) margins, pretreatment image guidance modality/frequency, and method of image verification, as well as questions regarding the utility and value of IGRT. Online image verification was defined as images checked and corrected prior to the day’s treatment. Offline image verification was defined as images obtained prior to treatment and then verified prior to the following day’s treatment. Associations between IGRT practice patterns and PTV margin size were examined using a linear regression model.

RESULTS: Of 671 responses (11%), 70 were nonphysician, resulting in 601 evaluable responses. The majority of respondents used IGRT (99%) for at least one fraction, with cone-beam computed tomography (CBCT) being the most commonly used modality (85%). Daily CBCT was obtained most frequently for intact prostate (63%), followed by prostatic fossa (60%), head and neck (H/N) (52%), pelvic intensity-modulated RT (51%), lung (50%), esophagus (40%), central nervous system (39%), and breast (7%). Regardless of imaging modality, daily online or offline image verification was the most common schedule (range: 72%–96% daily, 4%–24% weekly, and 1%–3% first few fractions only). Online image verification was most common for H/N (92%) and least common for breast (77%), with first-few-fractions–only online schedules most common for all disease sites except breast. The majority of respondents felt comfortable with therapists verifying IGRT independent of a physician (54%) and did not believe IGRT techniques negatively impacted clinical productivity (53%) or the physician-patient relationship due to excessive interruptions (57%). Additionally, the majority of respondents agreed that for pediatric cases, the benefits of IGRT outweighed the risks of additional radiation exposure (85%). No association was seen between IGRT frequency or method of verification and PTV margin size (P > .05 for all comparisons).

CONCLUSION: IGRT use is widespread, without standardization of pretreatment imaging modality, frequency, or verification process. Additionally, PTV margin size selection does not appear to be based on IGRT frequency or method of verification. Further research aimed at optimizing IGRT techniques is needed to ensure accurate, safe, timely, and cost-effective treatment delivery.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
Related Content